Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes
Background: Elevated levels of somatostatin blunt glucagon counterregulation during hypoglycemia in type 1 diabetes (T1D) and this can be improved using somatostatin receptor 2 (SSTR2) antagonists. Hypoglycemia also occurs in late-stage type 2 diabetes (T2D), particularly when insulin therapy is ini...
Main Authors: | Ninoschka C. D’Souza, Julian A. Aiken, Emily G. Hoffman, Sara C. Atherley, Sabrina Champsi, Nadia Aleali, Dorsa Shakeri, Maya El-Zahed, Nicky Akbarian, Mehran Nejad-Mansouri, Parinaz Z. Bavani, Richard L. Liggins, Owen Chan, Michael C. Riddell |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1302015/full |
Similar Items
-
Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes
by: Emily G. Hoffman, et al.
Published: (2024-01-01) -
EXPRESSION OF INSULIN, GLUCAGON, SOMATOSTATIN, AND PANCREATIC POLYPEPTIDE IN THE PANCREAS OF THE EURASIAN MOORHEN (Gallinula chloropus)
by: Ahmed Abdellatif
Published: (2023-07-01) -
Current and future therapies to treat impaired awareness of hypoglycemia
by: Erica L. Macon, et al.
Published: (2023-10-01) -
Somatostatin receptors in congenital hyperinsulinism: Biology to bedside
by: Mirjam E. van Albada, et al.
Published: (2022-09-01) -
Hypoglycemia Unawareness—A Review on Pathophysiology and Clinical Implications
by: Laura Hölzen, et al.
Published: (2024-02-01)